Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 3/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.78 |
| ▸ | GSK3B | P49841 | 1/20 | 0.73 |
| ▸ | CA2 | P00918 | 1/20 | 0.70 |
| ▸ | PIM1 | P11309 | 3/20 | 0.63 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.61 |
| ▸ | MYC | P01106 | 1/20 | 0.59 |
| ▸ | MAX | P61244 | 1/20 | 0.59 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.58 |
| ▸ | CLK1 | P49759 | 1/20 | 0.58 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.58 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8309671 | 1.00 | NAT1 (1.00) | NAT1PDE4BGSK3BCA2PIM1 | |
| SCHEMBL18103028 | 0.92 | NAT1 (0.85) | NAT1PDE4BGSK3BCA2PIM1 | |
| SCHEMBL19999112 | 0.90 | NAT1 (0.81) | NAT1PDE4BGSK3BCA2PIM1 | |
| SCHEMBL8310325 | 0.88 | PDE4B (1.00) | NAT1PDE4BGSK3BCA2PIM1 | |
| SCHEMBL8310322 | 0.88 | PDE4B (1.00) | NAT1PDE4BGSK3BCA2PIM1 | |
| SCHEMBL18103022 | 0.87 | NAT1 (0.77) | NAT1PDE4BGSK3BCA2PIM1 | |
| SCHEMBL13499562 | 0.87 | NAT1 (0.76) | NAT1PDE4BGSK3BCA2PIM1 | |
| SCHEMBL8193222 | 0.87 | NAT1 (0.76) | NAT1PDE4BGSK3BCA2PIM1 | |
| SCHEMBL15347653 | 0.87 | NAT1 (0.76) | NAT1PDE4BGSK3BCA2PIM1 | |
| SCHEMBL8193225 | 0.87 | NAT1 (0.76) | NAT1PDE4BGSK3BCA2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| WO-2016154255-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | UNIVERSITY OF MIAMI (US) | 2016-09-29 | — | — | WO | disclosed |
| EP-0915090-A1 | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1999-05-12 | — | — | EP | disclosed |
| US-5716975-A | NONTOXIC RHODANINE DERIVATIVES; ANTIDIABETIC AGENTS, CATHEPSIN D INHIBITORS, B-AMYLOID PROTEIN REDUCTION | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| US-5661168-A | ADMINISTERING RHODANINE DERIVATIVES TO CONTROL DIABETES | ELI LILLY AND COMPANY (US) | 1997-08-26 | — | — | US | disclosed |
| US-5523314-A | RHODANINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0587377-A2 | Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | NAT1 867/4885PDE4B 3826/4885GSK3B 1070/4885 |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NOTCH1, CBFB, HES1 | NAT1 867/4885PDE4B 3826/4885GSK3B 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.